ReCode Therapeutics is a genetic medicines company that specializes in mRNA and gene correction therapeutics.
ReCode Therapeutics is a genetic medicines company that specializes in mRNA and gene correction therapeutics.
Drug Delivery📍 Menlo Park, CAFounded 2015
Current Valuation
$700M
as of 2023-Q3
PRIVATE
QL Price
$700M
0% vs last round
QuantLogix's current estimate for ReCode Therapeutics, published 2026-09-27 — in line with the last disclosed round of $700M (2023-Q3).
Confidence
low
Basis
round anchored
What backs this price
Last disclosed round
$700M
2023-Q3
weight 0.13
How this price has held up
No round has priced for ReCode Therapeutics since QuantLogix began publishing a price for it, so there is nothing to grade yet. The claim above is on the record from 2026-09-27 and will be graded against the next priced round. See the full accuracy record →
Which publicly-traded funds already hold it, what $10,000 buys, and whether any route is open to you.
Cite this price as QuantLogix QL Price, ReCode Therapeutics, 2026-09-27 (edb809a13b048455).
The id pins this exact claim, so a citation stays checkable after the price moves.
Model estimate for research — not a quote, target price, or investment advice.
IPO Outlookprivate
Is ReCode Therapeutics going public?
No. ReCode Therapeutics is private and has not filed to go public. There is no S-1 on file.
What is ReCode Therapeutics' valuation in 2026?
ReCode Therapeutics is valued at $700M as of 2023-Q3, set by its Series B ($260M, Sep 2023). That is the last confirmed mark, not a live price — private shares do not trade continuously.
Has ReCode Therapeutics filed an S-1?
No public S-1 is on file for ReCode Therapeutics.
How much has ReCode Therapeutics raised?
ReCode Therapeutics has raised $342M in total, most recently a Series B of $260M in Sep 2023.
Is ReCode Therapeutics publicly traded — can you buy ReCode Therapeutics stock?
No. ReCode Therapeutics is a private company — its shares are not listed on any exchange and there is no ticker. The routes to exposure are pre-IPO secondary marketplaces and funds (accredited investors), employee tender offers when the company runs one, and public companies with read-through exposure. QuantLogix maps every route it can verify for ReCode Therapeutics on its Pre-IPO Access Desk.
Answers are derived from the roster record shown on this page — filing status, last round and confirmed marks. Where the record is silent, the answer says so rather than guessing.
Name-verified against lead sponsor "ReCode Therapeutics" on ClinicalTrials.gov as of 2026-09-19. Verify on ClinicalTrials.gov ↗
Talent Signal
Hiring trend
▶ Hiring steady
0% vs 2026-08
Open roles
1
via greenhouse
Product-build share
0%
engineering, research, product, design
Trajectory
steady
go-to-market push — Only 0% of open roles build product — hiring is concentrated in sales/marketing/ops (1 of 1 open roles are marketing).
Actively hiring with no tracked executive churn.
Open roles by month
Open roles by function
■ product-building ■ go-to-market / G&A
Join Our Talent Community
Counted from ReCode Therapeutics's live job board as of 2026-09-16; role functions classified from posting titles. Open-role counts are an activity signal, not headcount. Refreshed monthly.
BiopharmaBiotechnologyGeneticsPharmaceutical
Private-company numbers are not real-time. Reflects publicly disclosed valuations from press releases, news reports, and tender offers as of 2023-Q3. Refreshed quarterly.